Tenecteplase and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Tenecteplase
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines make bleeding more likely, so using them together adds up. Apixaban (Eliquis) is a blood thinner that keeps clots from forming. Tenecteplase is a powerful clot-buster given in the hospital, usually for an emergency like a heart attack or stroke. On their own, each one raises your bleeding risk. Put together, that risk gets higher.
The good news is that tenecteplase is only given in a closely watched hospital setting. Your care team keeps a close eye on you and can act fast if anything comes up. If you take Eliquis at home, always tell any medical team about it so they can plan safely.
Additive bleeding risk (PD interaction). Apixaban, a direct factor Xa inhibitor, plus tenecteplase, a fibrinolytic, produce additive hemostatic impairment and increased major bleeding risk. Neither is a prodrug; effect direction is additive, not metabolic.
- Direction/magnitude: increased major bleeding risk; magnitude unquantified.
- Onset: unspecified (acute in practice, as tenecteplase is bolus-dosed).
- Evidence: theoretical.
- Management: monitor clinically for external/internal bleeding; follow Hb, blood pressure, and coagulation parameters (PT/anticoagulation tests); observe surgical/wound drainage. Suspect bleeding if Hb falls or BP drops.
What happens
An increased risk of bleeding
Interaction Deep Dive
Taking an anticoagulant together with a fibrinolytic (eg, thrombolytic) agent may raise the likelihood of major bleeding because the effects are additive1. Two studies have shown that a thrombolytic agent can be safely given alongside low-dose 4 or low-intensity warfarin therapy (that is, an INR of 1.7 or below) 5. Nevertheless, when an anticoagulant must be combined with a fibrinolytic agent, patients should undergo clinical monitoring for indications of either external or internal bleeding. Monitoring through laboratory tests is likewise recommended 2. Drainage from surgical wounds should be watched closely. Bleeding should be suspected in the event of declining Hb levels or a drop in blood pressure 3.
Why it happens (mechanism)
Additive effects
How to manage this interaction
Tenecteplase is given by a hospital team during an emergency, so this combination is handled in a monitored setting.
- Keep taking your Eliquis exactly as prescribed and never start or stop it on your own.
- Make sure every medical team knows you take a blood thinner.
- Your care team may watch you closely, check blood counts (hemoglobin) and blood pressure, and run clotting tests to catch bleeding early.
- Report any unusual bruising, bleeding that will not stop, dark or bloody stools, pink or red urine, severe headache, or dizziness right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) In clinical studies of patients undergoing percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intervention (PCI), giving bivalirudin together with thrombolytic agents, glycoprotein IIb/IIIa inhibitors, warfarin, or heparin was linked to a higher risk of major bleeding events compared with patients who did not receive these concurrent medications 1. Any agent capable of raising the risk of hemorrhage should be stopped before starting desirudin therapy 2.
b) A Finnish study that assessed the combination of streptokinase with oral anticoagulants for treating DVT found that, even though reduced doses were used during the streptokinase infusion, warfarin administration caused no difficulties. Forty-four patients were first given warfarin 0.5 mg along with streptokinase 600,000 international units. Streptokinase 600,000 international units/hour was then maintained for 3 days, after which phlebography was carried out to assess clearing of the thrombotic occlusion. If lysis was not complete, therapy was continued for another 3 days. Where required, warfarin was administered to maintain a protein phosphatase (PP) activity level of 0.1 to 0.2. Bleeding led to stopping treatment in 8 of the 44 patients (18.2%). Although this study records simultaneous use of oral anticoagulants and streptokinase, both the anticoagulant and streptokinase were begun at the same time. Because 3 to 5 days are needed before hypoprothrombinemia develops, these patients did not undergo the genuine interaction in which the thrombolytic effect of streptokinase produces hypoprothrombinemia as a result of concurrent warfarin use 4.
c) In a study examining registry data from 45,074 patients who received IV tissue plasminogen activator for acute ischemic stroke, there was no meaningful rise in the risk of symptomatic intracerebral hemorrhage or death among patients on warfarin therapy with an INR of 1.7 or less (n=768) compared with patients not receiving warfarin (n=43,651), after adjustment for age, stroke severity, and comorbidities 5.
Common questions
Can I take Tenecteplase and Apixaban together?
Combining apixaban with tenecteplase adds up two bleeding risks, so your care team monitors you closely for bleeding while these are used together. Keep taking Eliquis as prescribed and make sure every provider knows about it. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Tenecteplase and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Tenecteplase and Apixaban interaction managed?
Tenecteplase is given by a hospital team during an emergency, so this combination is handled in a monitored setting. Keep taking your Eliquis exactly as prescribed and never start or stop it on your own. Make sure every medical team knows you take a blood thinner. Your care team may watch you closely, check blood counts (hemoglobin) and blood pressure, and run clotting tests to catch bleeding earl… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Tenecteplase or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (5)
- Product Information: ANGIOMAX(R) IV injection, bivalirudin IV injection. The Medicines Company, Parsippany, NJ, 2005.
- Product Information: Iprivask(TM), desirudin for injection. Aventis Pharmaceuticals Inc. Bridgewater, NJ, 2003.
- Product Information: Xarelto(R) oral film-coated tablets, rivaroxaban oral film-coated tablets. Bayer HealthCare (per manufacturer), Leverkusen, Germany, 2008. DailyMed
- Jarvinen P, Aromaa U, Roiha M, et al: Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klin Wochenschr 1978; 56:801-804. PubMed
- Mazya MV, Lees KR, Markus R, et al: Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013; 74(2):266-274. DOI
Keep reading about Apixaban
Keep reading about Tenecteplase
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist